ALLMedicine™ Mastocytosis Center
Research & Reviews 616 results
https://doi.org/10.1038/s41375-021-01406-y 10.1016/S0145-2126(01)00038-8 10.1111/j.1365-2362.2007.01807.x 10.1016/S0145-2126(01)00028-5 10.1073/pnas.92.23.10560 10.1038/leu.2015.24 10.1016/j.jaci.2004.02.045 10.1158/0008-5472.CAN-16-2234 10.1182/blood-2016-09-731893 10.1182/blood-2006-06-028100 10.1016/j.jaci.2010.02.019 10.1182/blood-2009-10-249979 10.3324/haematol.2010.034553 10.1016/j.jaci.2013.06.020 10.1111/cea.12369 10.1016/j.bone.2011.07.004 10.1182/blood-2006-04-015545 10.1016/j.jaci.2009.05.003 10.1111/all.14248 10.1016/j.jaip.2018.09.024 10.1016/S2352-3026(19)30166-8 10.1111/1523-1747.ep12468882 10.1016/j.jaci.2008.11.018 10.1002/ajh.24382 10.1182/blood-2009-02-205237 10.1038/leu.2016.190 10.7150/thno.51872 10.1200/JCO.19.00640 10.1182/bloodadvances.2018026245 10.1016/S2352-3026(20)30400-2 10.1111/all.12409 10.1038/leu.2015.284 10.1182/blood.2018886507 10.1038/modpathol.2011.84 10.1159/000059404 10.1016/j.iac.2018.04.003 10.1111/bjh.17567
Leukemia Zanotti R, Bonifacio M et. al.
Sep 22nd, 2021 - In the current classification of the World Health Organization (WHO), bone marrow mastocytosis (BMM) is a provisional variant of indolent systemic mastocytosis (ISM) defined by bone marrow involvement and absence of skin lesions. However, no addit...
Journal of the European Academy of Dermatology and Venere... Brockow K
Sep 18th, 2021 - Unsatisfactory agreement using current classification of maculopapular cutaneous mastocytosis.|2021|Brockow K,|diagnosis,
Blood Henriques A, Muñoz-González JI et. al.
Sep 9th, 2021 - Circulating tumor mast cells (CTMC) have been identified in the blood of a small number of patients with advanced systemic mastocytosis (SM). However, limited data exists about their frequency and prognostic impact in patients with mast cell activ...
The International Journal of Clinical and Experimental Hy... Retornaz F, Grino M et. al.
Sep 4th, 2021 - Mastocytosis is an orphan disease associated with many systemic symptoms, chronic handicap, and potentially marked social consequences despite improved therapies. In this study, the authors aimed to measure the effect of 2 hypnosis sessions on mas...
International Archives of Allergy and Immunology; Komulainen J, Siiskonen H et. al.
Aug 30th, 2021 - Mast cells and their major protein, the serine proteinase tryptase, can be involved in cutaneous photodamage and carcinogenesis. The serum test of tryptase (S-tryptase) measures total tryptase protein (active tryptase and inactive protryptases), a...
Guidelines 2 results
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.
Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...
Allergy Valent P, Escribano L et. al.
May 20th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...
Drugs 189 results see all →
News 47 results
CHEST Physician; Richard Mark Kirkner
Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.
Jul 9th, 2019 - However, the Expert Committee still did not define either the length of time of flushing or nontransient erythema. It also did not specify convex surfaces of the face with periocular sparing as the characteristic pattern or provide additional info.
Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.
Liman AD, Gandhi A et. al.
Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.
Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.